期刊文献+

脑胶质瘤增敏放疗的分子生物学研究进展 被引量:3

下载PDF
导出
摘要 恶性胶质瘤是成人最常见的原发性中枢神经系统肿瘤。平均存活时间少于1年的这种状况在过去的30年里并没有得到显著改善。胶质瘤明显的辐射抗性是其预后差的重要原因之一。对胶质瘤恶性表型及辐射抗性分子机制的深入了解有利于产生新的针对性治疗策略。近年对于胶质瘤的分子生物学研究发现了一些其生长和生存途径中共同的畸变位点,并针对这些畸变位点,产生了新的放疗方法,目的是为了提高功效,减少毒性。
出处 《国际神经病学神经外科学杂志》 2009年第6期552-555,共4页 Journal of International Neurology and Neurosurgery
  • 相关文献

参考文献26

  • 1Kornblith PL, Wlker M. Chemotherapy for malignant glioma. J Neurosurg, 1988, 68(7) :1-17.
  • 2Black PM. Brain tumor, part I. N Engl J Med, 1991 ,324 (3) :1471-1476.
  • 3Von Deimling A, Fimmers R, Schmidt MC, et a l. Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol, 2000,59 ( 6 ) : 544-558.
  • 4Sathornsumetee S, Reardon DA, Desjardins A, et al. Molecularly targeted therapy for malignant glioma. Cancer, 2007, 110(1) :13-24.
  • 5Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin Cancer Res, 2006, 12 (5) :4738-4746.
  • 6Tabatabai G, Frank B, Wick A, et al. Synergistic antiglioma activity of radiation and enzastaurin Ann Neurol, 2007, 61(2) :153-161.
  • 7Van den Bent MJ, Brandes A, Rampling R, et al. Randomized phase II trial of erlotinib (E) versus temozolomide ( TMZ ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26, 034. Proc Am Soc Clin Oncol, 2007, 25(2) :2005.
  • 8Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J. Clin Oncol, 2007, 25 (16) :2288-2294.
  • 9Chakravarti A, Berkey B, Robins HI, et al. An update of phase II results from RTOG 0211 : A phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma. Proc Am Soc Clin Oncol,2006 24(12) :1527.
  • 10Schwer AL, Damek DM, Kavanagh BD, et al. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas, Int J Radiat Oncol Biol Phys, 2008, 70: (4) 993-1001.

二级参考文献21

  • 1张庆林,孟庆海,金澎.神经干细胞治疗胶质瘤实验研究的现状和前景[J].中华神经外科疾病研究杂志,2007,6(3):193-195. 被引量:5
  • 2Reya T,Morrison SJ,Clarke MF,et al.Stem cells,cancer,and cancer stem cells[J].Nature,2001,414(6859):105-111.
  • 3Raso A,Negri F,Gregorio A,et al.Successful isolation and long-term establishment of a cell line with stem cell-like features from an anaplastic medulloblastoma[J].Neuropathol Appl Neurobiol,2008,34(3):306 -315.
  • 4Liu G,Yuan X,Zeng Z,et al.Analysis of gene expression and chemoresistance of CD133^+ cancer stem cells in glioblastoma[J].Mol Cancer,2006,5:67.
  • 5Blean AM,Howard BM,Taylor LA,et al.New strategy for the analysis of phenotypic marker antigens in brain tumor-derived neurospheres in mice and humans[J].Nenresurg Focus,2008,24(3 -4):E28.
  • 6Joo KM,Kim SY,Jin X,et al.Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas[J].Lab Invest,2008,88(8):808 -815.
  • 7Zheng X,Shen G,Yang X,et al.Most C6 cells are cancer stem cells:evidence from clonal and population analyses[J].Cancer Res,2007,67(8):3691 -3697.
  • 8Wang J,Sakariassen PQ,Tsinkalovsky O,et al.CDI33 negative giioma cells from tumors in nude rats and give rise to CD133 positive cells[J].Int J Cancer,2008,122(4):761 -768.
  • 9Loebinger MR,Giangreco A,Groot KR,et al.Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade[J].BrJ Cancer,2008,98(2):380 -387.
  • 10Platet N,Mayol JF,Berger F,et al.Fluctuation of the SP/non-SP phenotype in the C6 glioma cell line[J].FEBS Lett,2007,581(7):1435-1440.

共引文献7

同被引文献54

  • 1席桂发,王宝峰,王和平,叶飞,郭东生,雷霆.EGF和AG1478对GL15细胞增殖、侵袭和GFAP表达的影响[J].中华神经外科疾病研究杂志,2007,6(4):302-306. 被引量:6
  • 2Walker MD, Alexander E Jr, Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg, 1978, 49 (3) : 333-343.
  • 3Karim AB, Afra D, Comu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult:European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council Study BR04: an interim analysis. Int J Radiat Oncol Biol Phys, 2002,52(2) :316-324.
  • 4Reni M, Cozzarini C, Panucci M G, et al. Irradiation fields and doses in glioblastoma muhiforme: are current stantdards adequate. Tumori, 2001 , 87 ( 2 ) : 85 +90.
  • 5Mirimanof RO, Stupp R. Radiotherapy in low-grade gliomas: Cons. Semin Oneol,2003,30(6 Suppl 19) :34-38.
  • 6Papagikos MA, Shaw EG, Stieber VW. et al. Lessons learned from randomised clinical trials in adult low-grade glioma. Lancet Oncol, 2005, 6 (4) :240-244.
  • 7Shaw EG, Tatter SB, Lesser GJ, et al. Current controversies in the radiotherapeutic management of adult low-grade glioma. Semin Oncol, 2004, 31 (5) :653-658.
  • 8Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol, 2004,31 ( 5 ) : 635 -644.
  • 9Scott CB, Scarantino C, Urtasun R et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant giloma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys, 1998, 40(1) : 51-55.
  • 10Roa W, Brasher PM, Bauman G. et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiform : a prospective randomized clinical trial. J Clin Oncol, 2004,22(11) :1583-1588.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部